期刊文献+

监测恶性肿瘤化疗前细菌感染患者血清降钙素原水平对抗菌药使用的影响 被引量:4

Monitoring of Bacterial Infection in Patients With Malignant Tumor Before Chemotherapy Serum Procalcitonin Levels on The Impact of Antimicrobial Drug Use
下载PDF
导出
摘要 目的:探讨监测恶性肿瘤患者化疗前并发细菌感染血清降钙素原(PCT)水平对临床优化抗菌药使用的价值。方法:114例患者分成观察组和对照组。对照组(45例)予常规治疗,跟据患者临床症状体征选用抗菌药;观察组(69例)监测血清PCT水平、超敏C反应蛋白(hsCRP)、血常规及血培养的变化,据此制订优化抗菌药方案。观察2组抗菌药疗程、住院天数、抗菌药费用、抗菌药使用强度(AUD),以及二重感染和药品不良反应(ADR)发生情况。结果:观察组患者血清PCT水平与患者细菌感染严重程度有关。观察组的抗菌药疗程、住院天数、抗菌药费、AUD,以及二重感染和ADR等指标均优于对照组,差异有统计学意义(P<0.05或0.01)。结论:监测PCT动态值对恶性肿瘤患者化疗前细菌感染的诊断及临床抗菌药短期优化治疗有实用价值。 Objective:Discussion of monitoring in patients with malignant tumor chemotherapy before concurrent bacterial infection of serum procaleitonin ( PCT ) levels on clinical optimization of antimierobial drug use value. Methods: 114 cases were divided into observation group and control group. The control group (45 cases) was treated with convention- al therapy, according to the clinical symptoms of patients with selection of antibacterial drugs; The observation group (69 cases) monitoring serum PCT level, super sensitive c-reactive protein (hsCRP), blood routine and the change of blood cul- ture , pursuant to which the formulation of to optimize antibacterial drug scheme. Observation two groups antibacterial treat- ment, hospitalization days, antibacterial drug costs, antibacterial use density (AUD) , as well as the incidence of superin- feetion and adverse drug reactions (ADR). Results:The observation group patients serum PCT levels with bacterial infec- tion in patients with severe degree. The Observer Group antibacterial drug treatment, the number of days of hospitalization, antimierobia] drugs costs, AUD, as well as the superinfeetion and ADR ete indicators are better than the control group, the difference was statistically significant (P 〈 0.05 or 0.01 ). Conclusion: Monitoring of PCT dynamic value on malignant tumor before chemotherapy patients with bacterial infection before the diagnosis and clinical antibacterial short-term optimal treatment has the practical value.
出处 《药物流行病学杂志》 CAS 2013年第4期161-163,共3页 Chinese Journal of Pharmacoepidemiology
基金 湛江市财政资金科技专项竞争性分配项目(编号:2011D0301)
关键词 血清降钙素原 恶性肿瘤 细菌感染 抗菌药 合理用药 Serum proealcitonin Malignant tumor Bacterial infeetion Antimierobials Rational drug use
  • 相关文献

参考文献9

  • 1Assiot M, Gendrel D, Carsin H, et al. High serum procalci- tonin concentrations in patients with sepsis and infection[J]. Lancet, 1993,341 (8844) :515-518.
  • 2Sehuttrumpf S, Binder L, Hagemann T,et al. Utility of pro- calcitonin concentration in the evaluation of patients with ma- lignant diseases and elevated C-reactive protein plasma con- centrations [ M ]. CID, 2006.43.
  • 3卫生部,国家中医药管理局,总后卫生部.抗菌药物临床应用指导原则[S],卫医发[2004]285号.2004,8.19.
  • 4卫生部办公厅.2011年全国抗菌药物临床应用专项整治活动方案[Z].卫办医政[2011]56号.2011.
  • 5李曼,徐先顺,覃正碧.某三级甲等医院干预前后住院患者的抗菌药物使用强度分析[J].中国药房,2012,23(38):3572-3574. 被引量:9
  • 6Maruna P, Nedelnikova K, Gurlieh R. Physiology and ge- netics of Procalcitonin [J]. Physiol Res,2000, 49 (Suppl. 1) :S57-S61.
  • 7Christ-Crain M, Muller B. Biomarkers in respiratory tract infections:diagnostic guides to antibiotic prescription prog- nostic markers and mediators [ J ]. Eur Respir J, 2007, 30 (3) :556-573.
  • 8周舍典,周甘平,黄云平,罗一玲,陈华.我院常见病原菌的耐药性与抗菌药的临床选用[J].中国药师,2010,13(9):1317-1320. 被引量:12
  • 9周舍典,周甘平,邝丽,蔡静月,黄云平,陈毓强,付秀莲.我院抗菌药物临床应用动态监测的综合干预[J].中国药师,2011,14(6):838-840. 被引量:12

二级参考文献20

  • 1刘忠,刘立,陈冠容.武汉25所医院2004~2005年头孢菌素应用分析[J].药物流行病学杂志,2006,15(5):289-291. 被引量:16
  • 2陈敏,尹维佳,周陶友,乔甫,吕晓菊,刘力克.综合性医院抗菌药物应用管理成效[J].中华医院感染学杂志,2007,17(1):71-74. 被引量:39
  • 3何慧丽,鲁燕侠,严莲珍.喹诺酮类抗菌药物的临床应用[J].中华医院感染学杂志,2007,17(6):725-725. 被引量:26
  • 4卫生部,国家中医药管理局,总后卫生部.抗茵药物临床应用指导原则[S].卫医发[2004]285号.
  • 5卫生部办公厅.关于抗茵药物临床应用管理有关问题的通知[s].卫办医政发[2009]38号.
  • 6卫生部,国家中医药管理局,总后卫生部.抗菌药物临床应用指导原则[s]/卫医发[2004]285号.,2004.
  • 7卫生部.医院感染管理办法[S].2006.48号.
  • 8卫生部,国家中医药管理局,总后卫生部.抗茵药物临床应用指导原则[S].卫医发[2004]285号.2004.
  • 9The US Agency for International Development (USA ID). How to Investigate Antimicrobial Drug Use in Hospitals : Selected Indicators [ C ]. Arlington : Management Sciences for Health, Ine ,2002.8-25,30.
  • 10卫生部办公厅.关于做好全国抗茵药物临床应用专项整治活动的通知[S].卫办医政发[2011]56号.

共引文献126

同被引文献40

引证文献4

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部